These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 4757116)

  • 1. [Prognosis in myelomatosis treated with prednisone and cytostatics].
    Hansen OP; Jessen B; Videbaek A
    Ugeskr Laeger; 1973 Jun; 135(23):1169-73. PubMed ID: 4757116
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognosis of myelomatosis on treatment with prednisone and cytostatics.
    Hansen OP; Jessen B; Videbaek A
    Scand J Haematol; 1973; 10(4):282-90. PubMed ID: 4764610
    [No Abstract]   [Full Text] [Related]  

  • 3. [Analysis of the results of treatment of multiple myeloma].
    Snigurowicz J; Rostkowska J; Kraj M; Mariańska B
    Acta Haematol Pol; 1979 Oct; 10(4):227-35. PubMed ID: 539350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple myeloma without initial paraproteins.
    Kim I; Harley JB; Weksler B
    Am J Med Sci; 1972 Oct; 264(4):267-75. PubMed ID: 4630526
    [No Abstract]   [Full Text] [Related]  

  • 5. Prognostic factors and the effect of alkylating agents on survival in multiple myeloma. A review of 80 patients.
    Matzner Y; Benbassat J; Polliack A
    Isr J Med Sci; 1977 Aug; 13(8):797-807. PubMed ID: 408296
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cytomorphological, immunochemical and therapeutic aspects of multiple myeloma].
    Maroncelli P; Casalino C
    Minerva Med; 1973 Feb; 64(8):337-57. PubMed ID: 4120544
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic factors and survival in multiple myeloma. Analysis of 91 cases treated by melphalan and prednisone.
    Gobbi M; Cavo M; Savelli G; Baccarani M; Tura S
    Haematologica; 1980 Aug; 65(4):437-45. PubMed ID: 6774915
    [No Abstract]   [Full Text] [Related]  

  • 8. Improved survival times in multiple myeloma treated with melphalan, prednisone, cyclophosphamide, vincristine and BCNU: M-2 protocol.
    Case DC; Lee DJ; Clarkson BD
    Am J Med; 1977 Dec; 63(6):897-903. PubMed ID: 605911
    [No Abstract]   [Full Text] [Related]  

  • 9. Chemotherapy of multiple myeloma.
    Ungaro P
    J Ky Med Assoc; 1973 Dec; 71(12):805-7. PubMed ID: 4766737
    [No Abstract]   [Full Text] [Related]  

  • 10. Monitoring myelomatosis.
    Hobbs JR
    Arch Intern Med; 1975 Jan; 135(1):125-30. PubMed ID: 1111461
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Myelomatosis: comparison of melphalan and cyclophosphamide therapy.
    Br Med J; 1971 Mar; 1(5750):640-1. PubMed ID: 4926948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Combination chemotherapy (modified M-2 protocol) for multiple myeloma].
    Iwata Y; Karitani Y; Tanaka I; Kobayashi T; Ohno T; Kageyama S; Katayama N; Kataoka Y; Kamio N; Ohota C
    Rinsho Ketsueki; 1984 Sep; 25(9):1380-7. PubMed ID: 6549187
    [No Abstract]   [Full Text] [Related]  

  • 13. [Primary treatment results in myeloma disease using a cytostatic preparation].
    Iavorkovskiĭ LI; Soloveĭ DIa; Udris OIu; Riauzova LIu; Bliumental' RIa
    Probl Gematol Pereliv Krovi; 1981 Aug; 26(8):36-40. PubMed ID: 7301789
    [No Abstract]   [Full Text] [Related]  

  • 14. Normal immunoglobulins in multiple myeloma: effect of melphalan chemotherapy.
    Alexanian R; Migliore PJ
    J Lab Clin Med; 1970 Feb; 75(2):225-33. PubMed ID: 5414404
    [No Abstract]   [Full Text] [Related]  

  • 15. [Therapy of plasmacytoma].
    Gassel WD; Sodomann CP
    Ther Ggw; 1980 Sep; 119(9):980-1005. PubMed ID: 7466705
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma.
    Sakalová A; Holománová D; Mikulecký M; Mistrík M; Lipsic T; Steruská M
    Neoplasma; 1993; 40(6):351-4. PubMed ID: 8289966
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multiple myeloma in stage I. Evaluation of the initial therapy].
    Zapatero A; Blanco L; Sevilla F; Escribano L; Odriozola J; Montalbán C
    Rev Clin Esp; 1985 May; 176(8):388-91. PubMed ID: 4023320
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiple myeloma. Prolonged periods of remission can be produced in myelomatosis with alkylating agents.
    Leone LA; Albala MM
    R I Med J; 1965 Sep; 48(9):478-85. PubMed ID: 5213242
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of myelomatosis--M.R.C. trial.
    Galton DA
    Br Med J; 1971 May; 2(5757):323-4. PubMed ID: 4930211
    [No Abstract]   [Full Text] [Related]  

  • 20. Multiple myeloma. II. The value of melphalan.
    Bernard DB; Lynch SR; Bothwell TH; Bezwoda WR; Stevens K; Shulman G
    S Afr Med J; 1974 May; 48(24):1026-8. PubMed ID: 4835772
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.